This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. By 2030, analysts estimate that this figure could rise to over $74 billion.ĭirector Investor Relations and Corporate Communicationsįax + 49 (0) 89 - 86 46 67 // Disclaimer: Currently, global sales of biosimilars are estimated at more than $15 billion. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. In the coming years, many of these biotech drugs will lose their patent protection – and by 2025, medications with revenues of approximately USD 100 billion will be off patent. Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. Formycon currently has six biosimilars in development. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to clinical phase III as well as the preparation of dossiers for marketing approval. Stefan Glombitza.ġ Eylea ® is a registered Trademark of Regeneron Pharmaceuticals Inc.įormycon (ISIN: DE000A1EWVY8 / WKN: A1EWVY) is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. We are very pleased that with FYB203 we have filed our second biosimilar candidate in the ophthalmology space that is likely to become even more important in the coming years in light of the aging population.”, says Formycon CEO Dr. "Our latest MAA submission once again demonstrates the high performance and reliability of the entire #TeamFormycon. In the first nine months of 2023, Eylea reached global sales of around US$ 7 billion ], underlining its status as the currently best-selling drug in the field of anti-VEGF therapies. It inhibits the vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina. Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (Klinge) announce that the marketing authorization application (MAA) for FYB203, a biosimilar candidate for Eylea® 1 (Active ingredient: Aflibercept) has been submitted to the European Medicines Agency (EMA).Įylea® is used in the treatment of neovascular age-related macular degeneration (nAMD) and other severe retinal diseases. Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea ® (Aflibercept)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |